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ABSTRACT
Background: Streptococcus pneumoniae is a leading
cause of illness in children. Seven-valent pneumococcal
conjugate vaccine (PCV-7), recently approved in the
United States, is the ﬁrst vaccine to provide protective
immunity against pneumococcal disease in children under
the age of 2. PCV-7 is nearly 100% effective in preventing
invasive pneumococcal infections and has been shown to
signiﬁcantly decrease the incidence of pneumonia and
otitis media.
Objective: The objective of this study was to evaluate the
health outcomes, costs, and cost-effectiveness of vaccina-
tion with PCV-7, compared with no vaccination for chil-
dren in Spain.
Methods: A health state model was used to determine the
health and economic outcomes in vaccinated and unvac-
cinated groups among children less than 5 years old. This
analysis was conducted for a 10-year time horizon, begin-
ning with initial vaccinations. Information on the burden
of pneumococcal disease, in terms of data on the inci-
dence and seroprevalence of disease, was collected from
published and unpublished records, supplemented, and
veriﬁed by Spanish pediatric and infectious disease
experts. The efﬁcacy of PCV-7 was based on updated ﬁnd-
ings of the Kaiser Permanente Efﬁcacy Study. A cost-of-
illness estimate for each pneumococcal disease was
determined using decision tree analysis that considered
direct and indirect costs. A birth cohort analysis com-
pared the expected cost of vaccinated populations to age-
matched unvaccinated populations.
Results: Implementing a PCV-7 vaccine program in Spain
in a birth cohort of 360,000 is expected to save approx-
imately 16 lives and 132,000 cases of pneumococcal dis-
ease over 10 years, resulting in total savings estimated at
€81 million (ESP13.5 billion), of which €43.5 million
(ESP7.1 billion) are direct medical savings. At a vaccine
cost up to €56.87 per dose (ESP9,462, the total cost of
vaccinating a birth cohort of 360,000 will be offset by the
total savings owing to reduced morbidity.
Conclusions: Implementing a universal PCV-7 vaccina-
tion program in Spain will signiﬁcantly decrease the
mortality and morbidity associated with pneumococcal
infections in young children. At an assumed cost of
€48.56 (ESP8,080) per dose, PCV-7 vaccination of
Spanish children under the age of 5, followed over a 10-
year period, is cost saving from the societal perspective
and cost-effective from the payer perspective at €22,500
per LYG (ESP3,734,713), comparing favorably with
other preventive programs in Spain.
Keywords: cost-effective, pneumococcal, vaccination,
Spain, PCV-7.
Introduction
Streptococcus pneumoniae (or pneumococcus) is a
leading cause of illness in children and can cause ill-
ness and death among the elderly and persons who
have certain underlying conditions [1]. Several
countries in Europe and North America have rec-
ommended the broad use of the currently available
pneumococcal polysaccharide vaccine in every per-
son at the age of 60 years and above or for people
over the age of 2 years who have increased risks of
pneumococcal disease [2]. Nevertheless, the useful-
ness of this vaccine is limited by the fact that it is not
immunogenic in children younger than 2 years of
age. This limitation prevents the protection of the
most important high-risk populations for pneumo-
coccal disease.
The S. pneumoniae organism exists as an encap-
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sulated bacterium in which a polysaccharide sur-
rounds the cell wall. S. pneumoniae is composed of
over 40 antigenically distinct polysaccharide cap-
sule formations that separate all pneumococcus
into different “serogroups.” Some of these sero-
groups include more than one “serotype,” with
each serotype displaying a slightly different
polysaccharide composition. Although immuno-
logic cross-reactivity has never been observed
between serogroups, a great deal of evidence has
shown the occurrence of cross-reactivity among
the serotypes of the same serogroup. Because S.
pneumoniae is actually composed of a multitude of
antigens, rather than just one as in the case of Hae-
mophilus inﬂuenzae serotype b (Hib) and Neisseria
meningitides serogroup C (meningococcus C), its
treatment and prevention is signiﬁcantly more
complicated.
The seven-valent pneumococcal conjugate vac-
cine (PCV-7) is the ﬁrst vaccine to provide protec-
tive immunity against pneumococcal disease in
children under the age of 2, and has been approved
by the American Food and Drug Administration for
pediatric use. The safety proﬁle of PCV-7 has been
evaluated in more than 19,000 children, and results
of clinical trials indicate that the vaccine is safe and
nearly 100% effective in preventing invasive pneu-
mococcal infections. Vaccination has also been
shown to signiﬁcantly decrease the incidence of
pneumonia and otitis media episodes [3–5]. Fur-
thermore, unlike the 23-valent vaccine currently
available, PCV-7 has been shown to decrease the
nasopharyngeal carriage of S. pneumoniae in vacci-
nated children, which may prevent the emergence of
antibiotic-resistant strains of pneumococcus and
protect unvaccinated individuals against pneumo-
coccal disease by herd immunity [6,7]. As stated by
an authority in the ﬁeld of pneumococcal disease
and immunization: “The public health importance
of pneumococcal conjugate vaccines may be better
measured by their impact on nasopharyngeal car-
riage of S. pneumoniae and the corresponding
reduction in the occurrence of not only otitis media
but also invasive pneumococcal disease, including
meningitis and other invasive infections caused by
antibiotic-resistant pneumococci” [8].
The demonstrated clinical and humanistic bene-
ﬁts of this vaccine are necessary, but may not be suf-
ﬁcient to justify its use in publicly and privately
funded immunization programs. The impact of
PCV-7 on the cost burden of pneumococcal disease
must also be considered. This vaccine’s expected
impact on disease cost as well as disease outcome
(e.g., death, morbidity, life-long disability) can be
determined and expressed in relation to one another
as a cost-effectiveness ratio.
Background
S. pneumoniae causes invasive infections such as
bacteremia and meningitis and respiratory tract
infections such as pneumonia, otitis media, and
sinusitis. S. pneumoniae is associated with high
morbidity and mortality among children, especially
at young ages. In addition, although penicillin
formerly served as the most speciﬁc antimicrobial
agent for the destruction of pneumococcus, rates of
penicillin-resistant S. pneumoniae isolates have
been reported in 47.7% in children less than 5 years
of age in 1996 in Catalonia, Spain [9]. Also data
from 3921 strains of S. pneumoniae isolated from
1990 to 1999 in children aged 0 to 14 years in Spain
suggests an overall antibiotic resistance reported at
61% to penicillin and 35.2% to erythromycin [10].
Many pneumococcal strains resistant to penicillin
exhibit resistance to other antimicrobial agents
further complicating treatment of pneumococcal
infections.
Invasive Pneumococcal Disease
Asymptomatic or occult bacteremia is common
between 6 months and 2 years. It can resolve spon-
taneously or may evolve into pneumonia, cellulites,
sepsis, meningitis, and death. The incidence of inva-
sive pneumococcal disease (IPD) among Spanish
children <2 years of age has been reported at 61.3
per 100,000 per year [11]. Higher rates (55–72 per
100,000 per year) were observed in North America
for children of the same age [12,13].
Pneumococcal meningitis, a type of IPD, is a very
serious condition that may lead to death or severe
brain damage. An estimated 5% to 25% of Spanish
children with bacterial meningitis will die from this
condition and S. pneumoniae forms were associated
with the highest mortality of any type of bacterial
meningitis [14–16]. In another study, a 9.3% mor-
tality rate and 36.4% sequelae rate were associated
with pneumococcal meningitis in infants in Spain
[17]. Incidence rate of pneumococcal meningitis for
children under the age of 2 years has been reported
at 8.26 per 100,000 per year [17]. The peak inci-
dence rate for S. pneumoniae meningitis has been
observed in children less than 1 year of age [16].
Noninvasive Pneumococcal Disease
Pneumonia, or an infection of the lung, is most
common in early childhood and it is the cause of
more than one million deaths a year in developing
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countries [18]. S. pneumoniae probably accounts
for 25% to 30% of causes of pediatric community-
acquired pneumonia [19]. The diagnosis of pneu-
mococcal pneumonia is complicated by the fact that
it is frequently associated other bacteria or viruses.
For example, S. pneumoniae is the most prevalent
coinfection of respiratory syncytial virus [20,21]. A
signiﬁcant challenge in pneumonia management is
to distinguish between viral and bacterial pneumo-
nia, which has prompted physicians in Spain to
prescribe oral antibiotics in the treatment of pneu-
monia despite the fact that the etiology of the dis-
ease in unknown.
Acute otitis media (AOM) is one of the most
common diseases and one of the leading causes of
antibiotic prescription in Spanish pediatric clinical
practice [22]. Although the majority of AOM epi-
sodes resolve spontaneously without requiring anti-
microbial therapy, low spontaneous resolution rates
were observed for children less than 2 years of age
when S. pneumoniae was the pathogen involved
[23], and between 24% to 32.5% of bacterial acute
otitis media in Spanish children is reportedly due to
infection with S. pneumoniae [24]. A study of 867
Spanish children found an overall incidence of
AOM of 20.55 per 100 per year in children less
than 5 years of age [25]. Rates of recurrence are
particularly high and American data suggest that by
3 years of age almost 50% of children will have suf-
fered from three or more episodes of AOM [26].
The Seven-Valent Pneumococcal Conjugated Vaccine
The advent of a novel PCV-7 that is both safe and
effective in reducing pneumococcal infections in
children less than 2 years of age is a promising
development in the prevention of pneumococcal
disease [3,4]. PCV-7 is composed of seven pneumo-
coccal polysaccharides each conjugated to a
CRM197 protein, a nontoxic mutant of diphtheria
toxin carrier. PCV-7 contains the serotypes 4, 6B,
9V, 14, 18C, 19F, and 23F, which have been esti-
mated to represent 72.5% of the IPD isolates
among Spanish children less than 6 years of age
[27].
Methods
Using Markov cohort simulation modeling tech-
niques described previously by Sonnenberg and
Beck [28] and Beck et al. [29], a health state tran-
sition model was developed to estimate the cost-
effectiveness of vaccination with PCV-7 for children
in Spain less than 5 years of age. This health state
transition model was intended to assess the cost-
effectiveness of vaccination by comparing outcomes
and costs of vaccinated children against the out-
comes and costs associated with age-matched,
unvaccinated children over a 10-year time horizon.
The model incorporates six possible health states,
four of which represent various pneumococcal ill-
nesses, one representing the “well” state of health,
and one representing death. The model assumes
that each patient is always in one of several discrete
health states for each of twenty 6-month intervals
over the 10-year simulation. Figure 1 provides an
illustration of the health state transition model. The
speciﬁc health states are as follows: well, meningitis,
bacteremia, pneumonia, otitis media, and death.
Because it has been assumed that children are born
free of pneumococcal disease, children enter the
simulation in the “well” health state and as time
progresses they can transition to the other states for
a 6-month period or remain in the same health state
according to predetermined transition probabilities.
These transitions probabilities deﬁne the time-
dependent probabilities associated with each of the
potential outcomes for the children in the simula-
tion. For example, the probability associated with
the contracting meningitis is deﬁned for each child
as  a  function  of  the  child’s  age  and  the  number
of cycles the process has undergone. Transitions
between health states are not only a function of the
number of cycles the process has undergone, but
also a function of current state of health and
whether or not the individual has been vaccinated.
To track the overall costs of vaccination and the
cost of treating the various pneumococcal diseases,
each health state was assigned a value, equal to the
estimated cost of residing in that particular health
state for a given time interval. The cost of each
pneumococcal disease was estimated for both a
payer’s perspective, costs borne by the Spanish
health-care system, and a societal perspective, costs
borne by the country of Spain, to perform cost-
Figure 1 Markov model simulation that incorporates six possible
health states of  well, meningitis, bacteremia, pneumonia, otitis media,
and death.
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effectiveness analysis from both of these perspec-
tives. The estimation of these costs was performed
using separate decision analytic models speciﬁc to
each pneumococcal disease considered in our anal-
ysis. A clinical management algorithm, for example,
a decision tree model, was constructed for each
pneumococcal disease through a review of available
literature and supplemented by consultation with a
panel of Spanish experts to ensure accurate repre-
sentation of typical, current practice patterns in
Spain. The panel provided estimates of the success
and failure rates for each therapy, as well as decision
nodes estimates, which represent opportunities for a
physician to make a therapeutic choice in any given
clinical management algorithm.
As an example, Figure 2 depicts the decision
tree used to determine the expected cost of bacter-
emia in Spain. The probability and cost for the
societal perspective, as well as the weighted cost
of each outcome (branch), of the tree are also
given for illustration. Similar decision trees were
constructed and populated in collaboration with
the panel for otitis media (17 branches), general
pneumonia (4 branches), and pneumococcal men-
ingitis (6 branches). For meningitis, the long-term
sequelae known to be associated with episodes of
meningitis were also considered in the decision
tree analysis. The probability of each complica-
tion, mental retardation, hearing loss, focal neuro-
logic deﬁcit, and chronic seizure disorder, along
with an estimate of complication costs for the ﬁrst
year of treatment, was included in the cost of
meningitis.
Although the payer analysis was limited to the
evaluation of direct medical costs, the societal per-
spective reﬂects the overall burden of pneumococcal
disease in Spain, including the costs to the Spanish
health-care system and those additional morbidity
and mortality costs borne by society. The societal
analysis included all of the direct medical expenses
from the payer perspective, plus direct nonmedical
and indirect costs associated with the treatment
of pneumococcal disease. Direct nonmedical costs
include all of the disease-related costs not included
in a health-care system, such as transportation costs
and baby-sitting fees. Indirect costs are the costs
associated with lost economic productivity owing to
morbidity (i.e., time spent on the treatment of
infected children by nonprofessional caregivers,
usually parents) or to death (i.e., lifetime productiv-
ity losses owing to premature death).
Analyses
Four speciﬁc analyses were performed to assess
the beneﬁts of vaccination: expected health out-
comes, expected cost, break-even cost, and cost-
effectiveness analyses. As previously described,
these analyses considered both a payer’s perspective
and a societal perspective. Additionally, two distinct
scenarios were evaluated. The primary scenario,
identiﬁed as the patient-level analysis, compared
cohorts of vaccinated and unvaccinated infants
(<7 months of age) assuming that the vaccinated
cohort would follow a standard dosing schedule.
This analysis, which pertains to cohorts of children
initially vaccinated between the ages of 6 weeks and
7 months, considers the hypothetical scenario in
which approximately 360,000 Spanish births are
vaccinated with PCV-7 annually. A secondary sce-
nario identiﬁed as the population-level analysis was
performed to evaluate the merits of vaccination for
all children less than 5 years of age in Spain at the
time of vaccine introduction to the market. In this
analysis, all children less than 5 years of age are
considered eligible for vaccination. The population-
level model combines published projections of the
eligible Spanish pediatric population for 2001 to
2010 [30], all possible dosing schedules and
cohorts, the impact of late vaccination, and assump-
tions on vaccine usage over time.
Expected health outcomes. The health state tran-
sition model was used to estimate the expected
health outcomes, in terms of cases of pneumococcal
illness and death for vaccinated and unvaccinated
cohorts of children in Spain. These results are a
function of the assumed age-speciﬁc incidence rates
of disease combined with the estimated proportion
of the cases owing to the relevant S. pneumoniae
serotypes and vaccine efﬁcacy rates, only in the vac-
cinated cohorts, applicable to each speciﬁc infection
(see “Model Assumptions”). The results were then
compared for both cohorts, unvaccinated and vac-
cinated, to determine the cases of pneumococcal ill-
Figure 2 Decision analysis tree depicting the decision tree used to
determine the expected cost of  bacteremia in Spain. The probability
and cost for the societal perspective, as well as the weighted cost of
each outcome (branch), of  the tree are also given for illustration.
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ness and deaths prevented over a 10-year period
through vaccination. This analysis determines the
“effectiveness” portion of the cost-effectiveness
ratio (see “Cost-Effectiveness Analysis”).
Expected cost and break-even cost analysis. The
expected cost of the vaccinated and unvaccinated
cohorts were determined through the use of the per
episode cost-of-illness estimates, derived from dis-
ease-speciﬁc decision tree models, combined with
the number of episodes of disease, based on the
expected health outcomes analysis. For each distinct
time period, or cycle, of the model, the number of
episodes of each illness was multiplied by the esti-
mated per episode cost of illness. The totals for each
time period were then added together, assuming
that future costs are discounted at 3% per year, to
yield a total expected cost of pneumococcal disease
for the entire analysis period for each cohort
(expected cost analysis). To calculate the break-even
cost, the net expected savings in the costs of treating
pneumococcal disease (direct or direct and indirect
depending upon perspective) was ﬁrst calculated by
subtracting the expected cost of pneumococcal dis-
ease for the vaccinated cohort from the expected
cost for the unvaccinated cohort. This net savings
was then used to calculate a per-dose break-even
cost for vaccination. The per-dose vaccine cost that
results in a total cost of vaccination equivalent to
the  total  resulting  savings  in  pneumococcal  dis-
ease cost is the break-even cost (break-even cost
analysis).
It should be emphasized that the break-even
analysis is limited by the fact that it only assigns an
economic value to the vaccine’s ability to lower the
direct and indirect costs associated with pneumo-
coccal diseases. It does not incorporate any meas-
urement of the humanistic value of the prevention
of S. pneumoniae-caused mortality. This beneﬁt is
evaluated thoroughly in the cost-effectiveness
analysis.
Cost-effectiveness analysis. The cost-effectiveness
analysis provides a synthesis of the vaccine’s com-
bined impact on the overall cost and health out-
comes associated with pneumococcal disease. In
this analysis, results were expressed in terms of the
following cost-effectiveness ratios: cost per life-year
gained (CELYG) and cost per episode avoided (CEEA).
The difference between the overall cost of the vac-
cinated and unvaccinated cohorts deﬁned the
numerator of the cost-effectiveness ratio and the
difference in outcomes (life-years or episodes of
disease) between the vaccinated and unvaccinated
cohorts deﬁned the denominator.
(1)
(2)
In the calculation of the numerator of each ratio, it
should be noted that this analysis assumed that the
overall cost for the unvaccinated cohort is equal to
the expected cost of pneumococcal disease pre-
viously described; however, the cost for the vacci-
nated cohort includes an assumed cost of
vaccination in addition to the disease cost. This vac-
cination cost accounts for both the price of the vac-
cine and any related costs that will be incurred by
administering the vaccine, such as nursing time for
the injection.
The denominator of the ﬁrst ratio (CE LYG), the
difference in life-years resulting from vaccination
(LYG), was approximated by assuming that each
child’s life expectancy is the equivalent of the cur-
rent life expectancy in Spain of 78.26 years [31].
Therefore, the LYG is calculated as the difference in
the number of estimated deaths for the vaccinated
and unvaccinated cohorts, multiplied by the esti-
mated remaining life expectancy in years, where
the remaining life expectancy is approximated as
78.26 years minus the child’s age at the time of
death. Although this is an approximation, because
most deaths occur in very young children, the error
will be negligible. Just as future costs are dis-
counted, future beneﬁts were similarly subject to
discounting. Future life-years saved was discounted
at 0% and 3% per year, and results are presented
using both assumptions.
The denominator of the second ratio (CEEA), epi-
sodes avoided (EA), is a measure of all pneumococ-
cal disease episodes avoided and was calculated by
summing all episodes of disease for the unvacci-
nated and vaccinated cohorts (i.e., meningitis cases
+ bacteremia cases + pneumonia cases + acute otitis
CE
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Unvaccinated cohort deaths
Vaccinated cohort deaths
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]
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media cases) and subtracting to determine the epi-
sodes avoided through vaccination.
All cost-effectiveness results have been reported
for both the payer and the societal perspective
over a range of vaccine costs from €0 to €90
(∼ESP15,000). Finally, it should be noted that to
avoid double-counting of the beneﬁts of vaccina-
tion, all costs of mortality (i.e., estimated future
productivity losses) were omitted in the determina-
tion of the societal cost-effectiveness ratios. This
consideration is not relevant for the payer perspec-
tive, because no costs of mortality were included in
this perspective.
Model Assumptions
Incidence rates. Age-speciﬁc incidence data for chil-
dren under 10 years of age were necessary for inclu-
sion in the model to estimate the frequency of
occurrence of pneumococcal diseases over time in
Spain. Based on available data for Spain, it was
assumed that the average incidence per 100,000
children <10 years of age was 3.4 cases per year for
pneumococcal meningitis and 27.5 cases per year
on for bacteremia [11,17,32]. Additionally, because
the vaccine efﬁcacy data against invasive disease
was speciﬁc to the seven unique S. pneumoniae
serotypes, an adjustment factor, the serotype cover-
age rate, was applied to ensure that the model con-
sidered only incident cases of disease caused by the
relevant serotypes. The serotype coverage rates used
in the analysis were a function of the speciﬁc type of
IPD, as well as the age of the child. For meningitis,
the average rate was 75%, and for bacteremia,
67.7%, through 10 years of age [33]. In the absence
of Spanish data for the incidence of noninvasive
pneumococcal diseases, data from Switzerland (K.
Muhlemann, Institute of Medical Microbiology,
University of Bern, Bern, Switzerland, unpublished
data) and Finland [34,35] were used as best availa-
ble conservative estimates representing the inci-
dence rates by age group for general pneumonia,
1,461 per 100,000 on average per year, and otitis
media, 60,864 per 100,000 on average per year.
Available annual incidence rates were converted to
semiannual values at 6-month transition probabili-
ties to be consistent with the time period of the
model. The age-dependent 6-month transition rates
used in the analysis are shown in Figure 3. Peak
incidence rates generally were observed during the
ﬁrst 2 years of age. Mortality rates of 9.3% and 1%
were assumed for meningitis [17] and bacteremia
[5], respectively. No mortality was assumed for
noninvasive pneumococcal diseases. Additionally,
because the vaccine efﬁcacy for IPD is based upon
only the serotype-speciﬁc cases of disease, all IPD
incidence data were “corrected” based on the esti-
mated proportion of IPD caused by the relevant
serotypes in Spain. For pneumococcal meningitis,
the prevalence of the relevant serotypes was esti-
mated to be 83.6% in children less than 2 years
of age, decreasing to 72.9% for those more than
2 years of age. Similarly for bacteremia, it was
assumed that the prevalence of the relevant sero-
types was 81.0% in children up to 2 years and
64.4% for those older than 2 years of age [33].
Vaccine efﬁcacy rates. Efﬁcacy rates for PCV-7 and
assumptions about the vaccine’s duration of protec-
tion were used to adjust the incidence of pneumo-
coccal disease among the vaccinated cohorts. The
model assumed a vaccine efﬁcacy rate of 97.4%
reduction in episodes of serotype-speciﬁc pneumo-
coccal meningitis and serotype-speciﬁc pneumococ-
cal bacteremia, as observed in the Northern
California Kaiser Permanente Efﬁcacy Study (NCK-
PES) randomized trial [5]. Nevertheless, not all
invasive diseases are due to the seven serotypes and,
therefore, as previously mentioned, the prevalence
of vaccine-related serotypes among all cases of IPD
was considered.
In this study, noninvasive disease was reduced by
11.4% for general pneumonia and 5.8% for general
otitis media. Efﬁcacy rates for non-IPD disease are
not based on the etiology of the disease (i.e., they
are not speciﬁc to S. pneumoniae-caused disease),
which explains why a relatively low reduction in
incidence was observed by the NCKPES. Efﬁcacy
rates also determined by this study were a 10.6%
reduction in recurrent AOM, a 24.9% reduction in
myringotomy procedures, and a 33% reduction in
episodes of severe pneumonia. These rates of lower
severity in cases of non-IPD observed among
the vaccinated children during the NCKPES were
Figure 3 Pneumococcal disease incidence rates (semiannual) in chil-
dren aged 6 to 10 years. The age-dependent 6-month transition rates
used in the analysis for each of  the four disease states.
Semi-Annual Rates of Pneumococcal Disease 
in children aged 0-10 years
0
20
40
60
80
100
120
0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 96 102 108 114 120
Age (in months)
D
is
ea
se
 E
pi
so
de
s
SP Bacteremia (per 100,000 per 6 months)
SP Meningitis (per 100,000 per 6 months)
SP Pneumonia (per 10,000 per 6 months)
Otitis Media (per 100 per 6 months)
 
Asensi et al.42
considered in our study through the development of
separate vaccinated and unvaccinated costs of ill-
ness to reﬂect this difference in disease severity and
resultant cost.
Immunologic studies of PCV-7 [36] and observa-
tional studies of the HIB protein conjugate [37]
indicate that PCV-7 will stimulate a long-lasting
antibody response and provide an extended dura-
tion of protection. Therefore, it was assumed that
for a period of 5 years following initial vaccination
of the primary age group (infants <7 months), dis-
ease incidence would be reduced by the clinically
observed efﬁcacy rates (e.g., 97.4% reduction in
incidence of serotype-speciﬁc IPD). The vaccine’s
efﬁcacy would then decrease by 3% per year for
years 6 to 10 after initial vaccination. For late-
vaccinated children (the catch-up population, 2 to 5
years old), 3 years of full efﬁcacy and a 3% decrease
thereafter were assumed. Because immunologic evi-
dence [36] indicates that this vaccine will remain
largely effective throughout the 10-year time hori-
zon of the cost-effectiveness model, the results
based on this assumption are presented. A compli-
ance rate of 100% was assumed for all vaccination
schedules.
Cost assumptions. Sources consulted to reﬂect the
costs relevant to the Spanish health-care perspective
(payer perspective) included the 1998 “Resultados
de la Gestion Analitica en los Hospitales del
INSALUD” [38] and 1999 “VADEMECUM” [39].
Table 1 lists the unit costs used to value the medical
resources consumed in the treatment of bacteremia
as identiﬁed by the clinical panel. Similar tables
were developed for each of the pneumococcal dis-
eases considered in the analysis.
Direct nonmedical costs were estimated based on
a study of the direct nonmedical costs of physician
visits, hospital days, and surgeries associated with
episodes of otitis media in the United States [40].
For indirect costs, the time lost by the nonprofes-
sional caregiver (e.g., parent, legal guardian) of a
child with pneumococcal disease was used to esti-
mate the amount of productive time that is lost to
the informal care of the child. It is assumed that a
parent or other nonprofessional caregiver will be
present for each physician visit, hospital day, or
ambulatory surgery that is necessary for the treat-
ment of a child’s episode of pneumococcal disease.
Based on the opinion of the Delphi panel, it was
assumed that 4 hours of productivity would be lost
on the part of the nonprofessional caregiver for each
outpatient physician visit or emergency room visit
that is necessary for the treatment of disease. By the
same method, 8 hours of lost time was associated
with each day spent by the child in a hospital ward,
intensive care unit, and/or ambulatory surgical pro-
cedure. Each hour lost was valued at €18.03
(ESP3000), the average hourly wage in Spain [41].
In addition to the productivity costs associated with
the morbidity of pneumococcal disease, an indirect
cost of S. pneumoniae-caused death, was included
to value the life-long productivity of the child that is
lost by society when that child dies of pneumococcal
disease. This indirect economic cost of death was
calculated by determining the average lifetime earn-
ings of a Spanish child with the same hourly wage,
an assumption of 35 hours of work per week, paid
employment for 50 weeks per year, and full-time
employment from the age of 20 to the age of 60. The
expected future earnings lost by mortality were dis-
counted by 3% to determine their present value. To
avoid double counting, no monetary value was
attributed to death in the societal cost-effectiveness
ratio (see “Cost-Effectiveness Analysis”).
Vaccine administration. The primary vaccination
schedule for PCV-7 is intended for newborns vacci-
nated from the age of 6 weeks to less than
7 months. These children receive doses at the ages
Table 1 Master unit costs (bacteremia unit costs)—Spain
Physician visits/hospital days Hours Wage Unit cost
Pediatric emergency room visit €78.16
Follow-up pediatrician visit
(established patient)
€47.81
Hospital day (pediatrics ward) €315.53
ICU day €480.81
Diagnostic tests
LP/CSF analysis (including C + S) €46.78
Blood C + S €11.98
Urine C + S €3.77
CBC with differential €4.68
Chem-7 €5.24
CT Head €77.19
CXR €10.53
C-reactive protein (CRP) €4.68
Coagulation tests (PT/PTT) €4.68
Blood gas €6.20
Microbiology tests
Oral antibiotics
Amoxil €0.00048*
Amoxil/Clavunate €0.00114*
Cefuroxime €0.00463*
Erythromycin €0.00902*
IV antibiotics
Cefotaxime €0.00717*
Ceftriaxone €0.01357*
Vancomycin €0.01742*
Indirect costs
Outpatient visit 4 €18.03 €80.54*
Inpatient care 8 €18.03 €152.66*
Transportation cost €8.41
*Unit cost per mg.
Note: Unit costs were used to value the medical resources consumed in the
treatment of  bacteremia as identiﬁed by the clinical panel in Spain.
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of 2, 3, and 4 months and one booster dose at the
age of 12 to 15 months. The patient-level analysis
analyzes this group of children exclusively and is
intended to reﬂect the “steady-state” implications
of vaccinating all Spanish infants according to this
dosing schedule.
The population-level analysis was performed to
reﬂect the scenario that exists when the vaccine ﬁrst
becomes available for use in Spain. Because vacci-
nation with PCV-7 may be performed at various
ages according to different dosing and administra-
tion schedules, when the product is ﬁrst made avail-
able for use in Spain a substantial number of older
unvaccinated children will be eligible for vaccina-
tion. To capture this transient situation, as the
population-level analysis included three different
catch-up vaccination groups, infant, toddler, and
child catch-up, ranging in age from 7 months to
5 years, in addition to the primary group. The
infant catch-up group includes children vaccinated
at or above 7 months, but less than 12 months of
age, with a vaccination schedule of two doses at
least 2 months apart, in addition to one booster
dose at the age of 12 to 15 months. The toddler
catch-up group includes those vaccinated at or
above 12 months but less than 24 months of age.
This group was scheduled to receive two doses at
least 2 months apart. The child catch-up group
encompasses those vaccinated at or above the age of
24 months, but less than 60 months of age. They
are scheduled to receive one dose.
In addition to reﬂecting multiple vaccine admin-
istration schedules, the population-level analysis
was also designed to incorporate an estimated vac-
cination rate or population coverage. Speciﬁcally,
the population-level analysis assumed during the
ﬁrst year of vaccination, assumed to be 2003 in
Spain, 95% of the eligible children in all age cate-
gories would be vaccinated by the end of year 1.
This rate of 95% will remain steady for the remain-
der of the 10-year analysis period. This assumption
reﬂects the likelihood that upon vaccine introduc-
tion, while most children may be vaccinated, others
may never be vaccinated, and still some may not be
vaccinated immediately but will receive vaccina-
tions at a later time under a different administration
schedule. After evaluating all potential circum-
stances for the children considered in the 10-year
analysis, 59 unique patient populations were iden-
tiﬁed and were considered in the analysis. Assuming
uniform age distribution, approximately 90% of
the vaccinated population is expected to consist of
catch-up patients at the time of launch, with a rapid
fall-off in later years owing to an increase in pri-
mary patient vaccination as a result of increased
population coverage over time. The total estimated
vaccinated population for Spain as a function of
time is depicted in Figure 4.
Sensitivity Analysis
Comprehensive sensitivity analyses were conducted
to reﬂect the impact of critical assumptions on the
results of the analysis. First, to evaluate the upper
and lower bounds for the results of the analysis,
a multivariate sensitivity analysis was conducted
using the Crystal Ball® analysis tool (version 4.0g,
Decisioneering, Denver, 2002). In this analysis, each
of the assumptions included in the model was varied
simultaneously within a predeﬁned range (10,000
iterations) according to a probability distribution
intended to reﬂect the assumed variability of that
particular assumption. Speciﬁcally, cost-of-illness
estimates were allowed to vary within ±20% of
their assumed cost, according to a uniform proba-
bility distribution; the vaccine cost was varied by
±10% to reﬂect potential variability in vaccine
administration cost; and vaccine efﬁcacy estimates
were varied within their 95% conﬁdence intervals
determined in the NCKPES [3]. Additionally, the
incidence rate estimates were varied by ±50% of
their baseline values, to reﬂect the large potential
variability of both the all-cause incidence of disease,
as well as variability in the serotype-speciﬁc cases
for the IPD forms, and mortality rates associated
with meningitis were varied within the range of esti-
mates found in the literature (5%−25%). Finally, a
total of four simulations (40,000 total iterations)
were conducted to estimate the variability of both
the payer and the societal analyses, with and with-
out discounting of 3% applied to life-years.
Each of the iterations performed in this analysis
represented a unique combination of values for the
Figure 4 Population-level analysis: total expected patients in cohort
over time. The total estimated vaccinated population for Spain as a
function of  time.
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input assumptions, and for each of these combina-
tions of assumptions, a unique result was calcu-
lated. After all 10,000 iterations were completed for
each of the four separate simulations, the range of
results was summarized in the form of a frequency
distribution, which is then used to identify the
upper and lower bounds as deﬁned by the 95% con-
ﬁdence interval of simulated results. Additionally,
the multivariate analysis was used to measure the
sensitivity of the model to each of the input varia-
bles and thereby identify those variables to which
the model is most sensitive. These identiﬁed varia-
bles were then tested through univariate sensitivity
analysis, in which a particular assumption was var-
ied, and the corresponding impact on the results
was documented. The variables included in the uni-
variate sensitivity analysis were IPD incidence and
mortality rates, seroprevalence estimates, and the
cost of acute otitis media to determine their impact
on the cost-effectiveness values.
Results
Patient-Level Results
Expected health outcomes. Owing to the high efﬁ-
cacy of PCV-7, a signiﬁcant reduction in the mor-
tality and morbidity of pneumococcal diseases
following vaccination is expected. Within each
360,000-child annual birth cohort, it is expected
that 16 lives or 1,187 life-years will be saved from
PCV-7 vaccination over 10 years. In addition, PCV-
7 vaccination of 360,000 primary patients (0–
6 months) will achieve a reduction of approxi-
mately 91 episodes of meningitis and 751 episodes
of bacteremia as well as 5,800 cases of pneumonia
and 125,000 cases of otitis media over 10 years.
Table 2 illustrates the modeled health outcomes
over 10 years for a hypothetical birth cohort of
360,000 vaccinated primary patients (0–6 months)
and an identical cohort of unvaccinated children.
Expected cost analysis. Figure 5 presents the re-
sults of the cost-of-illness analysis for each health
state considered in the analysis for both the payer
perspective, indirect costs only, and the societal
perspective, direct and indirect costs. For the soci-
etal perspective, indirect costs ranged from a low of
31% (bacteremia) to a high of 55% (otitis media,
vaccinated) of the total expected cost. The de-
creased severity of AOM and pneumonia cases
among vaccinated children results in a lower cost,
which is also reﬂected in Fig. 5.
The signiﬁcant reduction in the number of pneu-
mococcal episodes will lead to savings in treatment
cost, either direct-only or direct and indirect,
depending on perspective, of pneumococcal infec-
tions. PCV-7 vaccination of each hypothetical birth
cohort of 360,000 children is expected to save a
total of €81 million (ESP13.5 billion) before
accounting for vaccine cost. This is based on the
difference of the 10-year expected societal cost of
the unvaccinated birth cohort (€426 million) and
the vaccinated cohort (€383 million). Of these €81
million, €42.5 million (ESP7.1 billion) will be saved
in direct medical expenses (payer) and €33.6 million
(ESP5.6 billion) will be saved in indirect and direct
nonmedical expenses (caregiver) and €4.9 million
(ESP812.5 million) over 10 years.
Vaccine break-even cost. The resulting 10-year per
patient societal savings owing to the vaccine was
calculated at €225 (∼€81 million/360,000) or a per-
dose break-even cost (BEC) of €56.87 per dose. This
break-even cost was assumed to include the price of
Table 2 Patient-level results: expected health outcomes
Patient type
Time 
horizon Bacteremia Meningitis Pneumonia
Otitis
media
Total 
disease Death
Primary vaccinated 10 years 23.11 3.71 46,785.99 2,065,893.00 2,112,705.80 0.54
Primary unvaccinated 10 years 773.62 94.43 52,609.89 2,191,036.31 2,244,514.24 16.34
Outcomes avoided 750.51 90.72 5,823.90 125,143.31 131,808.44 15.79
Note: The modeled health outcomes over 10 years for a hypothetical birth cohort of  360,000 vaccinated primary patients (0–6 months), an identical cohort of  unvac-
cinated children. and the outcomes avoided over 10 years.
Figure 5 Expected cost analysis. Presents the results of  the cost-of-
illness analysis for each health state considered in the analysis for both
the payer perspective (indirect costs only) and the societal perspective
(direct and indirect costs).
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the vaccine plus an administration fee, such as any
costs that are incurred during the administration of
the vaccine dose, such as the nursing or physician
time that will be necessary. Break-even cost from a
payer perspective is €29.86 per dose for the 10-year
time horizon. Figure 6 illustrates these ﬁndings.
Break-even costs were also calculated for chil-
dren in the nonstandard vaccination schedule. For
children who receive initial vaccination between
the ages of 7 and 11 months (catch-up 1, three-
dose schedule) BECs were calculated at €36.08
(ESP6004) for the payer analysis and €69.18
(ESP11,511) for the societal perspective. BECs for
the toddler catch-up population (12–23 months,
two-dose schedule) and the child catch-up popula-
tion (children 2–5 years, one dose) were deter-
mined, respectively, at €48.55 and €52.30 for the
payer analysis and €92.63 and €96.53, respectively,
for the societal analysis. These results suggest that
the vaccine is actually more cost-effective for
catch-up populations than for infants, mainly
resulting from the fact that fewer doses are
required.
Vaccine Cost-Effectiveness
The cost-effectiveness analysis was based on the
expected cost required to gain one extra life-year or
to avoid one pneumococcal illness by vaccination.
Because the cost-effectiveness is a function of the
cost of vaccination, Figure 7 presents the results of
the cost-effectiveness analysis of vaccination with
PCV-7 in terms of cost per life-year gained (LYG) as
a function of the vaccination cost (vaccine cost +
administration fee) from a payer and societal per-
spective for a 10-year time horizon.
At an assumed cost of approximately €48.56
(ESP8080) per dose of PCV-7, the vaccine is cost
saving from a societal perspective and cost-effective
(€22,500 per LYG) from a payer perspective. When
future LYGs were adjusted for discounting at 3%
per year (not shown in Fig. 7), the vaccine remained
cost saving from a societal perspective and cost-
effective (€60,300 per LYG) from a payer perspec-
tive. At the same vaccine cost, the cost-effectiveness
analysis per episode avoided (EA) was also cost sav-
ing from the societal perspective and cost-effective
(€202 per EA) from a payer perspective. Cost-
effectiveness was measured for a range of vaccine
costs (€35 to €55) to test the variability of values
based on realistic range of prices.
Population-Level Results
The population-level analysis ﬁndings represent the
anticipated aggregate result of universal vaccination
for all eligible groups of 0- to 5-year-olds in Spain,
over a 10-year analysis period. It is estimated that
such a vaccination program is expected to save
approximately 127 lives (9,530 life-years gained)
and 1.15 million cases of pneumococcal diseases
over 10 years. This corresponds to a reduction of
711 cases of meningitis, 6,200 cases of nonmenin-
gitis IPD, 52,000 cases of pneumonia, and 1.1 mil-
lion cases of otitis media. This signiﬁcant reduction
will result in total decrease in the cost of pneumo-
coccal disease treatment of €625 million (ESP104
billion) before accounting for vaccine cost. This
reduction in costs would be €349 million (ESP58
billion) in direct medical expenses (payer) and €277
million (ESP46 billion) in indirect and direct
Figure 6 Patient-level results: expected costs and break-even costs.
Break-even costs, assumed to include the price of  the vaccine plus an
administration fee (i.e., any costs that are incurred during the admin-
istration of  the vaccine dose, such as the nursing or physician time that
will be necessary) from both payer and societal perspectives over the
10-year time horizon.
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Figure 7 Patient-level results: cost-effectiveness analysis. Cost-
effectiveness in terms of  cost per life-year-gained (LYG) as a function
of  the vaccination cost (vaccine cost + administration fee) from a payer
and societal perspective for a 10-year time horizon.
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nonmedical expenses over 10 years (caregiver).
These estimated reductions in total cost of treating
pneumococcal disease were then converted to cor-
responding break-even costs for the population-
level analysis. The BECs for the population-level
analysis were found to be similar to the patient-level
ﬁndings at €27.20 (ESP4525) for the payer pers-
pective and €48.67 (ESP8098) for the societal
perspective over a 10-year time horizon.
Similar to the patient-level analysis, we calcu-
lated the cost-effectiveness of vaccination for both
the payer and the societal perspectives. Findings
for the population-level analysis were consistent
with the patient-level analysis. At €48.56 per dose,
universal PCV-7 vaccination program in Spain is
cost saving for the societal perspective and cost-
effective for the payer perspective over 10 years
at €28,800 Euros per LYG. When future life-years
saved was discounted at 3% per year, these CERs
remained cost saving for the societal perspective
and increased to €76,900 per LYG for the payer
perspective.
Finally, the cost per-episode avoided (EA) results
were again similar to the patient-level analysis. The
program is expected to cost approximately €240
per EA over 10 years from a payer perspective but
is expected to be cost saving from the societal
perspective.
Sensitivity Analysis
The results of the multivariate sensitivity analysis
are depicted in Table 3. The mean and 95% conﬁ-
dence interval for the cost/LYG are speciﬁed for the
payer and societal analyses, under the differing
assumption of 0% and 3% discount rate applied to
life-years. Multivariate sensitivity analysis for the
payer analysis also revealed that the model is most
sensitive to the incidence of otitis media and cost to
a lesser degree, as well as the incidence and mortal-
ity rate associated with meningitis. If the incidence
of otitis media had been overestimated by 100% in
the base-case payer perspective analysis (i.e., the
actual incidence is 50% less than value used), the
cost-effectiveness ratio would increase by 61%
from the assumed value of €22,500/LYG to
€36,100/LYG. If the value had been underestimated
by 50% in the payer perspective analysis the cost-
effectiveness ratio would be decreased to appro-
ximately €8,800/LYG. Similarly, a mortality rate
associated with meningitis that was actually 50%
lower than the assumption used in the base-case
payer analysis would result in an increase of the
cost-effectiveness ratio to approximately €30,400/
LYG, a 35% increase, whereas a value that was
50% higher than the estimated value would result
in a decrease of the cost-effectiveness ratio to
€14,700/LYG. Finally, variations in the incidence
rate of meningitis or the vaccine coverage rate, prev-
alence of the relevant serotypes, resulted in a similar
impact on the results of the analysis. For example,
an incidence rate or coverage rate that was 50%
below the assumed value would increase the cost-
effectiveness ratio for the payer analysis by 38% to
approximately €30,900/LYG, and a rate 50% above
the assumed value would decrease the cost-
effectiveness ratio by 22% to €17,500/LYG. It
should be noted that this last ﬁgure applies only to
potential underestimation of the incidence of men-
ingitis and not the vaccine coverage rate because the
assumed rate of 83.6% coverage could not increase
by 50% as this would result in a vaccine coverage
rate greater than 100%.
Findings in the societal analysis were similar,
with one notable exception. In the societal analysis,
the efﬁcacy of vaccination for pneumonia was
found to have a greater impact on the results than
meningitis incidence and mortality. If the efﬁcacy of
pneumonia were to actually be at the lower bound
of its 95% conﬁdence interval from the Kaiser efﬁ-
cacy study (1.3%) versus the assumed value of
Table 3 Multivariate sensitivity analysis results
Perspective
Discount rate:
life-years 
Mean value
(cost/LYG) SD
95% CI 
Lower
bound (cost/LYG)
Upper 
bound (cost/LYG)
Payer 0% €19,984 €10,636 €3,395 €45,245
Payer 3% €53,716 €28,252 €9,578 €120,977
Societal 0% –€3,500 €15,513 –€40,277 €26,582
Societal 3% –€12,413 €38,110 –€96,434 €55,652
Note: Multivariate sensitivity analysis was conducted using the Crystal Ball® analysis tool (version 4.0 g, Decision Analysis Inc., 2002). All assumptions were simulta-
neously and randomly varied according to predeﬁned ranges and probability distributions: Cost-of-illness estimates were allowed to vary within ±20% of  their assumed
cost, according to a uniform probability distribution; the vaccine cost was varied by ±10% to reﬂect potential variability in vaccine administration cost; vaccine efﬁcacy
estimates were varied within their 95% conﬁdence intervals determined in the NCKPES [3]; the incidence rate estimates were varied by ±50% of  their baseline values
(to reﬂect variability in incidence of  disease, and vaccine coverage rate); and mortality rates associated with meningitis were varied within the range of  estimates found
in the literature (5%−25%).
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11.4%, the mean value from the efﬁcacy study, the
societal results would remain cost saving. Neverthe-
less, the amount of savings would be reduced from
€11.8 million to €5.3 million. At the upper bound
of the 95% conﬁdence interval with an efﬁcacy of
20.5%; overall savings are estimated to increase to
€17.6 million.
Sensitivity analysis was also conducted on the
discounted cost-effectiveness values across a range
of realistic vaccine prices (€35 to €55) at the patient-
level to test the variability with the acquisition cost.
The CE/LYG values were cost savings from a soci-
etal perspective and displayed a range from €16,572
per LYG to €81,029 per LYG from the payer
perspective.
Discussion
PCV-7 is currently the most promising advance in
the prevention of pneumococcal disease among
infants available to date, and as such, universal vac-
cinations among Spanish children warrants serious
consideration. Ongoing clinical development of
other new vaccines to prevent S. pneumoniae infec-
tions will serve to provide broader serotype cover-
age and to further reduce the substantial impact of
pneumococcal diseases on patients and their care-
givers. As new vaccines become available, health
authorities must not only consider the economic
impact on payer budgets and the overall economic
impact on the population, but the decision-making
process required to evaluate the merits of a univer-
sal vaccination program must also carefully weigh
the costs incurred against the corresponding health
improvements realized. This research attempted to
evaluate the merits of a universal vaccination pro-
gram with PCV-7 within the conﬁnes of the current
available data. In this study, we have estimated that
a PCV-7 vaccination program among 0- to 5-year-
olds in Spain has the potential to save 127 lives as
well as to avoid almost 1.15 million cases of pneu-
mococcal disease over 10 years. This reduction of
incidence will translate into total savings in pneu-
mococcal disease treatment costs evaluated at €625
million without accounting for vaccination costs. At
an assumed vaccination cost of approximately
€48.56, PCV-7 is predicted to be a cost-effective
means of disease reduction (€240/EA and €29,000/
LYG) without accounting for indirect costs. These
results compare favorably in terms of cost-effective-
ness with other evaluations of preventive programs
in Spanish children. In particular, the cost per case
gained as a result of hepatitis B vaccination was
found ranging from €390 to €720 per episode
avoided in the region of Murcia in 1995, depending
on the vaccination program [42]. Vaccination pro-
grams in Spain against hepatitis A yielded CERs
ranging from €150 (selective) to €6000 (mass cam-
paign) per episode avoided in 1997 [43]. Further-
more, the cost/LYG, a more universal measure of
cost-effectiveness compares favorably with the cost-
effectiveness of numerous interventions which are
currently considered standards of care [44,45] and
falls well within established thresholds for accepta-
ble cost-effectiveness before considering the indirect
costs avoided [46]. When these indirect costs are
considered in the societal analysis, a PCV-7 vacci-
nation program is predicted to produce an overall
economic beneﬁt in the form of cost savings to soci-
ety, in addition to the previously mentioned health
beneﬁts.
Limitations in this evaluation should be carefully
considered for the purpose of medical/policy deci-
sion making. The results of the analysis appear to
be robust based on the ﬁndings of the multivariate
sensitivity analysis, which showed a relatively nar-
row range of results when all assumptions were
varied simultaneously. Nevertheless, the model has
been shown to be sensitive to certain key assump-
tions. As an example, overestimation of the preva-
lence of the relevant PCV-7 serotypes in this
analysis may result an overstatement of the cost-
effectiveness associated with vaccination, whereas
an underestimate of the incidence rate of meningitis
or the cost of otitis media might equally understate
the cost-effectiveness of vaccination. Other assump-
tions, such as the incidence of bacteremia and the
future lost productivity costs associated with early
death, although more uncertain, were not found to
have a substantial impact on the results of the anal-
ysis. In the context of this information, it is impor-
tant to fully evaluate the reliability of the key
assumptions made and their corresponding impact
on the results. For example, although the efﬁcacy
rates obtained from the Kaiser efﬁcacy trial are
considered to be reliable, it was assumed that the
protective effects of PCV-7 would last beyond the
time period demonstrated in the efﬁcacy trial.
Although this assumption was made in accordance
on the current understanding of PCV-7 immunol-
ogy [36] and was expressed by several infectious
disease experts at the physician’s panel meeting,
conducted for this study in Spain, its impact on the
results must be understood. In particular, in this
example, it is important to note that because the
peak incidence rates of disease occur during the
ﬁrst 2 years of age, it is the efﬁcacy assumptions
during this period of time that impact the results
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most directly. To evaluate the full 10-year time
period, an assumption on the extrapolation of the
efﬁcacy was necessary. Nevertheless, this assump-
tion had minimal impact on the results.
The impact of the incidence data on the results
highlights the need for research on the epidemiology
of pneumococcal noninvasive disease in Spain. In
particular, the incidence of otitis media and pneu-
monia by age group is unknown in Spain. To
address this lack of information, incidence from
Swiss (K. Muhlemann, Institute of Medical Micro-
biology, University of Bern, Bern, Switzerland,
unpublished data) and Finnish [34,35] studies were
used as a reasonable, best available estimate of dis-
ease incidence in Spain. Although these assumptions
are believed to be reasonable, it is important to note
the sensitivity of the analysis to otitis media inci-
dence and costs.
There also exist several important potential
beneﬁts of PCV-7 that have been demonstrated, but
cannot be considered in this economic analysis
because of a lack of quantitative data. One such
example relates to the limitation of the efﬁcacy data
and incidence assumptions to the seven relevant
serotypes. Despite that fact that cross-protection of
the pneumococcal serogroups related to PCV-7’s
seven serotypes (serotypes 9A, 9N, 9L, 18B, 18F,
and 19A) has been demonstrated qualitatively in the
Kaiser efﬁcacy trial [5], it was not included in the
economic analysis because speciﬁc cross-protection
efﬁcacy data was not determined by the Kaiser trial.
Similarly, the shortage of available incidence and
efﬁcacy data for other illnesses caused by S. pneu-
moniae has necessitated their omission from this
analysis, potentially resulting in an underestimation
of the beneﬁts associated with PCV-7. For example,
owing to the lack of reliable data on the incidence
and treatment of sinusitis in a pediatric population,
this disease state was not included in the model.
Therefore, the existing analysis does not account for
the savings in nonhospitalized invasive pneumococ-
cal disease, sinusitis treatment, or other diseases
associated with S. pneumoniae such as endocarditis,
arthritis, and peritonitis [47].
The most signiﬁcant unaccounted for beneﬁt of
PCV-7, however, is believed to be the capacity of
this vaccine to reduce the nasopharyngeal carriage
of S. pneumoniae. The reduction in nasopharyngeal
carriage of pneumococcus by PCV-7 has been
shown to prevent the emergence of antibiotic-
resistant strains of S. pneumoniae. The problem of
antibiotic-resistant pneumococci is increasing in
Spain, based on studies of invasive pneumococcal
disease and nasopharyngeal carriage [27]. Further-
more, PCV-7’s seven-valent formulation matched
over 86% of the resistant pneumococci identiﬁed in
Spain [27]. Vaccination is an available means of
reducing the irreversibly growing trend in antibiotic
resistance, as shown by studies of PCV-7 in South-
ern Israel [6] and the success of Haemophilus inﬂu-
enzae type b (Hib) conjugate vaccines [48]. This
trend is expected to cause greater morbidity and
mortality as well as signiﬁcantly raise the cost of
treatment for S. pneumoniae-related illnesses. These
expected increases in deaths and treatment costs are
not included in this evaluation.
PCV-7’s ability to reduce nasopharyngeal car-
riage indicates that vaccinating children will confer
protection against pneumococcal disease and anti-
biotic resistance to unvaccinated individuals via
herd immunity. Studies of vaccination with the nine-
valent pneumococcal conjugate vaccine have
demonstrated a reduction in the transmission of S.
pneumoniae and antibiotic-resistant S. pneumoniae
to their siblings [49]. Based on the ﬁndings of this
study, it is reasonable to assume that a similar herd
immunity effect will be realized by vaccination with
PCV-7. This reduction in carriage will protect
unvaccinated children and the elderly. The vast
majority of S. pneumoniae-caused mortality occurs
in the elderly [50,51]. Because the present analysis is
limited to only the pediatric population, this study
underestimates the deaths avoided and life-years
gained by vaccination.
As a ﬁnal observation, the deterministic model
design and secondary data employed in this evalu-
ation has introduced potential information bias to
the data analysis. In particular, the opinions of the
expert panel were assumed to be representative of
all clinical practices in Spain. The relatively small
number of clinicians that composed our panel might
result in a calculation bias inﬂuencing expected cost
of the pneumococcal diseases considered in this
evaluation. Additional limitations are also inherent
in the health state design. Owing to the fact that a
cohort-based model was used for the study, we were
unable to account for all possible patient variations,
such as subgroup variations and individual patient
characteristics. Hence, the results of this pharmac-
oeconomic study attempt to reﬂect the outcomes for
the average patient; however, the signiﬁcant individ-
ual patient variations and differences in practice
patterns may compromise the external validity (i.e.,
generalizability) of the evaluation. As an example,
extending full vaccine protection to at-risk patients,
such as immunocompromised or asplenic children,
may impact the expected number of deaths pre-
vented by PCV-7 vaccination. Nevertheless, the
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assumption that PCV-7 will be effective in immuno-
compromised children is based on the demonstrated
immunogenicity of the pneumococcal conjugate
vaccine in these individuals, unlike the 23-valent
polysaccharide vaccine [52,53].
Given the high morbidity and mortality of pneu-
mococcal diseases among children less than 5 years
of age, and considering that the current 23-valent
pneumococcal vaccine is not immunogenic in chil-
dren less than 2 years of age, Spanish authorities
should seriously consider universal PCV-7 vaccina-
tion among children. The vaccine has been demon-
strated to be safe; nearly 100% effective against
invasive pneumococcal disease and can prevent a
signiﬁcant number of episodes of otitis media and
pneumonia. Furthermore, the problem of increased
antibiotic resistance throughout the past decade in
Spain supports the need to consider vaccination as a
means of preventing pneumococcal disease among
children.
The authors thank Sameer Kotak for his invaluable con-
tribution to this research.
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